ArticleMedChemComm2016
Endless Resistance. Endless Antibiotics?
Article in MedChemComm, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Proteomic Insights into Bacterial Responses to Antibiotics: A Narrative Review.International journal of molecular sciences · 2025Review
- New Agents Are Coming, and So Is the Resistance.Antibiotics (Basel, Switzerland) · 2024Review
- Fungal Anthraquinone Photoantimicrobials Challenge the Dogma of Cationic Photosensitizers.Journal of natural products · 2023Article
- Phytochemical Variability, In Vitro and In Vivo Biological Investigations, and In Silico Antibacterial Mechanisms ofFoods (Basel, Switzerland) · 2022Article
- Fluoroquinolones Hybrid Molecules as Promising Antibacterial Agents in the Fight against Antibacterial Resistance.Pharmaceutics · 2022Review
- Antibacterial Discovery via Phenotypic DNA-Encoded Library Screening.ACS chemical biology · 2021Article
- Design, synthesis and biological evaluation of a halogenated phenazine-erythromycin conjugate prodrug for antibacterial applications.Organic & biomolecular chemistry · 2021Article
- Brief Overview of Approaches and Challenges in New Antibiotic Development: A Focus On Drug Repurposing.Frontiers in cellular and infection microbiology · 2021Review
- Towards the sustainable discovery and development of new antibiotics.Nature reviews. Chemistry · 2021Review
- Progress towards a stable cephalosporin-halogenated phenazine conjugate for antibacterial prodrug applications.Bioorganic & medicinal chemistry letters · 2020Article
- Constructing and deconstructing the bacterial cell wall.Protein science : a publication of the Protein Society · 2020Review
- Synthesis and Antibacterial Activity of Difluoromethyl Cinnamoyl Amides.Molecules (Basel, Switzerland) · 2020Article
- Modification at the 2'-Position of the 4,5-Series of 2-Deoxystreptamine Aminoglycoside Antibiotics To Resist Aminoglycoside Modifying Enzymes and Increase Ribosomal Target Selectivity.ACS infectious diseases · 2019Article
- The Supramolecular Self-Assembly of Aminoglycoside Antibiotics and their Applications.ChemistryOpen · 2019Review
- Norbornane-based cationic antimicrobial peptidomimetics targeting the bacterial membrane.European journal of medicinal chemistry · 2018Article
- Effects of the 1- N-(4-Amino-2 S-hydroxybutyryl) and 6'- N-(2-Hydroxyethyl) Substituents on Ribosomal Selectivity, Cochleotoxicity, and Antibacterial Activity in the Sisomicin Class of Aminoglycoside Antibiotics.ACS infectious diseases · 2018Article
- Total Syntheses of Bulgecins A, B, and C and Their Bactericidal Potentiation of the β-Lactam Antibiotics.ACS infectious diseases · 2018Article
- The Road from Host-Defense Peptides to a New Generation of Antimicrobial Drugs.Molecules (Basel, Switzerland) · 2018Review
- Understanding drug resistance will improve the treatment of bacterial infections.Nature reviews. Microbiology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The practice of medicine was profoundly transformed by the introduction of the antibiotics (compounds isolated from Nature) and the antibacterials (compounds prepared by synthesis) for the control of bacterial infection. As a result of the extraordinary success of these compounds over decades of time, a timeless biological activity for these compounds has been presumed. This presumption is no longer. The inexorable acquisition of resistance mechanisms by bacteria is retransforming medical practice. Credible answers to this dilemma are far better recognized than they are being implemented. In this perspective we examine (and in key respects, reiterate) the chemical and biological strategies being used to address the challenge of bacterial resistance.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.